Serum Immune Profiling in Paediatric Crohn's Disease Demonstrates Stronger Immune Modulation With First-Line Infliximab Than Conventional Therapy and Pre-Treatment Profiles Predict Clinical Response to Both Treatments.

"Conflict of Interest JCE received consultancy fees from Abbvie and Janssen, as well as research support from MSD and Nutricia. LdR: collaboration [e.g. involved in industry-sponsored studies, investigator-initiated study, consultancy] with Abbvie, Lilly, Takeda, Janssen and Pfizer; grant from ZonMw, ECCO, Pfizer. JS, HCR, IT, LMMC, MAC, MMEJ, MvP and YL declare no competing interests."

"Funding This investigator-initiated trial was financially supported by ZonMw [the Netherlands Organization for Health Research and Development] under project number 113202001, Crocokids [a Dutch fundraising organization that supports research on IBD in children], and an Investigator-Sponsored Research Award from Pfizer [Study ID WI213008]. The work presented in this paper was supported by stichting Dalijn and the collaborative TIMID project [LSHM18057-SGF] financed by the PPP allowance made available by Top Sector Life Sciences & Health to Samenwerkende Gezondheidsfondsen [SGF] to stimulate public–private partnerships and co-financing by health foundations that are part of the SGF. The funders of the study had no role in the study design, data collection, statistical analysis, interpretation or writing of the report."

"Trial registration number NCT02517684."